|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2003-10-13
|
|
pubmed:abstractText |
Anagrelide is an agent with a significant platelet-lowering activity in humans. Contrasting the wealth of clinical data, bone marrow (BM) changes during therapy have been relatively rarely studied; information is particularly lacking regarding specific features of megakaryocytopoiesis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1130-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14555309-Adult,
pubmed-meshheading:14555309-Aged,
pubmed-meshheading:14555309-Biopsy,
pubmed-meshheading:14555309-Blood Platelets,
pubmed-meshheading:14555309-Bone Marrow,
pubmed-meshheading:14555309-Chronic Disease,
pubmed-meshheading:14555309-Drug Evaluation,
pubmed-meshheading:14555309-Humans,
pubmed-meshheading:14555309-Immunohistochemistry,
pubmed-meshheading:14555309-Middle Aged,
pubmed-meshheading:14555309-Myeloproliferative Disorders,
pubmed-meshheading:14555309-Platelet Count,
pubmed-meshheading:14555309-Quinazolines,
pubmed-meshheading:14555309-Retrospective Studies,
pubmed-meshheading:14555309-Thrombocytosis
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
|
|
pubmed:affiliation |
Institute of Pathology, University of Cologne, Germany. j.thiele@uni-koeln.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
